What Is Buy and Bill? How It Works, and Why It Matters for Specialty Medication Reimbursement

Buy and bill is a specialty medication distribution and reimbursement model in which a healthcare provider purchases a drug directly, administers it to the patient, and then bills the patient’s third-party payer for both the medication and its administration. It is one of the foundational models in specialty drug distribution, predating both white bagging and brown bagging, and it remains widly used across oncology, rheumatology, neurology, and other specialty practices.

Understanding how buy and bill works and where it fits alongside other distribution models is essential for providers, payer relations teams, and anyone working in specialty pharmacy or medical practice revenue management.

What Is Buy and Bill?

Buy and bill is a reimbursement model in which a healthcare provider, typically a physician practice, infusion center, or hospital outpatient department, purchases a specialty medication directly from a manufacturer, wholesaler, or specialty distributor, administers it to the patient, and then submits a claim to the patient’s third-party payer for both the drug and its administration.

This model is most commonly used for:

•      Physician-administered drugs requiring clinical oversight, such as in-office infusions, injections, and biologics

•      Oncology and biologic drugs covered under the medical benefit (rather than the pharmacy benefit)

•      IV therapies and injectables that cannot be self-administered by patients

•      Rheumatology, neurology, and other specialty practices administering high-cost provider-administered drugs

•      Outpatient settings and infusion centers managing drug administration for complex or chronic conditions

•      Drugs sourced from a manufacturer, wholesaler, or specialty distributor and administered in-office

READ MORE: How Tech Can Streamline Pharma Operations

How Does Buy and Bill Work?

The buy and bill process follows a defined sequence of steps spanning drug acquisition, prior authorization, drug administration, claim submission, and payer reimbursement:

1.   The provider verifies the patient’s insurance eligibility and benefits, including whether the drug falls under the medical benefit or the pharmacy benefit.

2.   If required, the provider submits a prior authorization request and waits for approval from the third-party payer.

3.   Once approved, the provider orders the specialty medication directly from a manufacturer, wholesaler, or GPO.

4. The medication is shipped to the provider’s office or infusion center and placed into appropriate medication storage, including temperature-controlled conditions where required.

5.   The provider administers the drug at the patient’s visit.

6.   The provider submits a claim using the appropriate HCPCS J-code, along with administration codes and the drug’s NDC.

7.   The third-party payer reimburses the provider. Medicare typically reimburses at Average Sales Price (ASP) plus a percentage, such as ASP + 6%. Commercial payers may use different methodologies, so providers should not assume a single reimbursement rule applies across all payers.

Buy and Bill: Medical Benefit vs. Pharmacy Benefit

One of the most important distinctions in buy and bill is which benefit covers the drug. Under the medical benefit, drugs are billed as a medical claim using a J-code, which is the standard pathway for buy and bill. Under the pharmacy benefit, drugs flow through a specialty pharmacy, which is the model used in white bagging and brown bagging.

The same medication can sometimes be covered under either benefit, depending on the patient’s health plan. This makes benefits verification essential at the point of care because benefit type directly affects reimbursement, patient billing, and workflow.

‍

READ MORE: careviso Launches Electronic Medical Benefits Verification

Why Do Providers Use Buy and Bill?

•      Clinical control and supply chain control: Providers have full visibility into the drug’s chain of custody, medication storage, and verification, which reduces the risk of compromised drug integrity associated with brown bagging.

•      Streamlined patient experience: Patients arrive and receive treatment without managing a separate specialty pharmacy shipment or transporting medication themselves, improving treatment adherence and reducing delays.

•      Practice sustainability: The spread between drug acquisition cost and payer reimbursement has historically helped fund infusion centers and specialty practices, supporting medical practice revenue and long-term financial health.

What Are the Challenges of Buy and Bill?

•      Upfront capital risk: Providers purchase the medication before reimbursement. For high-cost specialty drugs, this creates financial risk if a claim is denied or a patient misses an appointment.

•      Operational burden: Facilities must manage inventory management, expiration tracking, medication storage, and medication waste disposal for a potentially large number of patients. This requires dedicated infrastructure and staff, and can create significant overhead for physician practices not originally built to function as in- house dispensing operations.

•      Claims complexity: Buy and bill requires precise coding, including the correct J-code, NDC, units billed, and administration codes. Errors result in denials, delayed payer reimbursement, or audits, creating revenue cycle risk.

•      Prior authorization: Most specialty drugs under buy and bill require prior authorization before drug administration. Without a confirmed approval, providers risk administering a drug they won’t be reimbursed for.

•      Payer restrictions: Some commercial payers no longer allow buy and bill for certain drugs, mandating white bagging or brown bagging instead. This creates a fragmented environment where the same drug follows a different pathway depending on the patient’s plan.

Buy and Bill vs. White Bagging vs. Brown Bagging

Buy and bill is one of three primary specialty medication distribution models. Here is how they compare:

•      Buy and bill: The provider purchases the specialty drug directly via drug acquisition from a manufacturer or specialty distributor, administers it in-office, and bills the medical benefit using a J-code. The provider assumes upfront financial risk and manages medication storage and inventory management.

•      White bagging: A specialty pharmacy dispenses the drug and ships it to the provider’s facility for administration. The drug is billed through the pharmacy benefit, and the provider does not take title to the medication.

•      Brown bagging: The specialty pharmacy ships the drug directly to the patient, who transports it to the provider for in-office administration. This model shifts logistical responsibility to the patient and raises concerns about drug integrity and supply chain control.

The right model depends on the payer’s requirements, the drug, and the care setting. Providers increasingly encounter situations where all three models apply across their patient population.

READ MORE: White Bagging vs Brown Bagging: What Specialty Pharma Should Know

What Buy and Bill Means for Patients

Buy and bill is generally the most seamless model for patients because there is no shipment to receive and no medication to transport. However, since drugs are billed under the medical benefit, patient billing may look different than expected. Copayments, coinsurance, and deductibles may not align with what patients pay at a pharmacy.

Understanding patient cost responsibility before treatment begins is critical to preventing surprise bills, protecting treatment adherence, and enabling effective patient care coordination.

How careviso Supports Buy and Bill Workflows

Successfully navigating buy and bill requires knowing whether the drug is covered under the medical or pharmacy benefit, whether prior authorization is in place, and what the patient’s out-of-pocket cost will be, all before the patient arrives for drug administration.

careviso’s seeQer platform now includes buy and bill details, enabling providers and patient support providers to verify eligibility, confirm benefit type, surface prior authorization requirements, and calculate patient cost responsibility for provider-administered drugs, all in one real-time workflow.

Book a demo to see it in action.

Frequently Asked Questions About Buy and Bill

Is buy and bill covered under the medical benefit or the pharmacy benefit?

Buy and bill is a medical benefit model. Providers bill for physician-administered drugs using a J-code, and the claim is submitted as a medical claim rather than a pharmacy claim. This distinguishes it from white bagging and brown bagging, which route drugs through the pharmacy benefit.

How are buy and bill drugs reimbursed?

Reimbursement varies by payer. Medicare typically reimburses at Average Sales Price (ASP) plus a percentage, such as ASP + 6%. Commercial payers may use different methodologies, so providers should confirm payer reimbursement terms before administering specialty drugs.

What is the role of average sales price (ASP) in buy and bill?

Average sales price is a benchmark used by Medicare to set reimbursement rates for physician-administered drugs. It is calculated from manufacturers’ reported sales data. For buy and bill, ASP determines how much Medicare will pay for a covered drug, typically plus a small percentage to cover administration fees and overhead.

Why do payers mandate white bagging instead of buy and bill?

Some commercial payers mandate white bagging to reduce drug costs by routing specialty drugs through contracted specialty pharmacies at negotiated rates. This limits the provider’s ability to capture the spread between drug acquisition cost and higher reimbursement ,and can create operational challenges for facilities accustomed to in-office drug acquisition.

How does buy and bill affect patient cost responsibility?

Because buy and bill drugs are billed under the medical benefit, patient billing involves medical benefit cost-sharing: copayments, coinsurance, and deductibles. This can differ significantly from what patients pay at a pharmacy under the pharmacy benefit. Understanding cost responsibility before treatment is essential to preventing surprise bills and supporting treatment adherence.

‍